Core Viewpoint - Incyte Corporation (03696) experienced a significant stock increase of over 4%, reaching HKD 63, following the announcement of a milestone payment from Menarini Group related to the MEN2501 project [1] Group 1: Financial Performance - As of the report, Incyte's stock rose by 4.56%, with a trading volume of HKD 1.323 million [1] - The company received approximately HKD 39 million as a milestone payment from Menarini for the MEN2501 project [1] Group 2: Project Development - MEN2501, previously known as ISM9682, is a small molecule inhibitor targeting the KIF18A protein, showing significant inhibitory activity against chromosomal instability cancers in preclinical data [1] - The collaboration with Menarini Group, valued at USD 550 million (approximately HKD 4.29 billion), aims to accelerate the development of transformative anti-tumor therapies [1]